Other Clinical Trial - Study to Evaluate the Efficacy & Safety Of

Updated 04/23/2024

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Non Muscle Invasive Bladder Cancer
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT02982395
Study type	Interventional
Source	Samyang Biopharmaceuticals Corporation
Contact
Status	Terminated
Phase	Phase 3
Start date	January 2017
Completion date	August 2018

See also
	Status	Clinical Trial	Phase
	Completed	`NCT06020807` - Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
	Recruiting	`NCT06167356` - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
	Withdrawn	`NCT01799499` - A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)	N/A
	Completed	`NCT02343614` - Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer	Phase 2
	Recruiting	`NCT05945108` - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
	Recruiting	`NCT06287541` - The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection	N/A
	Recruiting	`NCT06181266` - A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer	Phase 1
	Completed	`NCT06205277` - Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
	Completed	`NCT01731652` - Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer	Phase 2
	Recruiting	`NCT03421236` - Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)	Phase 1
	Active, not recruiting	`NCT04387461` - Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin	Phase 2
	Recruiting	`NCT06111235` - A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Phase 3
	Recruiting	`NCT02895620` - Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC	N/A
	Completed	`NCT01004211` - Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging	N/A
	Active, not recruiting	`NCT05981131` - Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)